Is Vitamin D Supplementation Effective for Low Back Pain? A Systematic Review and Meta-Analysis

Abstract

Background: Low back pain (LBP) is the leading cause of years lived with disability worldwide. Current intervention strategies are failing to reduce the enormous global burden of LBP and are prompting researchers to investigate alternative management strategies, such as vitamin D supplementation. Vitamin D supplementation appears to down regulate pro-inflammatory cytokines which lead to pain and up regulate anti-inflammatory cytokines that reduce inflammation. These mechanisms might explain the increasing interest in the use of vitamin D supplementation for LBP. Objectives: To determine whether vitamin D supplementation improves pain more than a control intervention for individuals with LBP. Study Design: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Methods: We performed searches in numerous electronic databases combining key words relating to “vitamin D” and “LBP” until March 2017. Studies were included if they investigated vitamin D supplementation in participants with LBP, provided there was a comparison intervention. There was no restriction on the type of LBP, the intervention parameters investigated, or the type of clinical trial (e.g., randomized, non-randomized). Two reviewers independently performed the selection of studies, extracted data, rated the methodological quality of the included studies, and evaluated the overall quality of the evidence using the Grading of Recommendations Assessment, Delevopment, and Evaulation (GRADE) approach. Results: After screening 3,534 articles, 8 clinical trials were included in this systematic review. There is very low quality evidence (based on the GRADE approach) that vitamin D supplementation is not more effective than any intervention (including placebo, no intervention, and other conservative/ pharmacological interventions) (continuous pain measures [0–100]: mean difference [MD] = -2.65, 95% confidence interval [CI]: -10.42 to 5.12, P = 0.504, n = 5; self-reported reduction in pain: pooled odds ratio [OR] = 1.07, 95% CI: 0.35 to 3.26, P = 0.906, n = 5) or placebo/no intervention for individuals with LBP (continuous pain measures: MD = 1.29, 95% CI: -3.81 to 6.39, P = 0.620, n = 4; self-reported reduction in pain: pooled OR = 1.53, 95% CI: 0.38 to 6.20, P = 0.550, n = 4), where ‘n’ is the number of studies included in the meta-analysis. These results did not change when we stratified the meta-analyses by the type of vitamin supplementation (vitamin D3 vs. alfacalcidol) or the type of LBP (non-specific vs. LBP resulting from osteoporosis or vertebral fractures). Limitations: The overall quality of evidence was “very low” due to the poor methodological quality and small sample sizes of the included studies. Conclusions: Vitamin D supplementation is not more effective than placebo, no intervention, or other conservative/pharmacological interventions for LBP (based on very low quality evidence). These results are consistent, regardless of the type of LBP or vitamin D supplementation. Until well-designed and adequately powered clinical trials suggest otherwise, the prescription of vitamin D for LBP cannot be recommended. PROSPERO Registration No: CRD42016046874. www.crd.york.ac.uk/PROSPERO/display_record. asp?ID = CRD42016046874 Key words: Vitamin D, low back pain, chronic low back pain, alfacalcidol, osteoporosis, vertebral fractures, serum 25-hydroxyvitamin D, systematic review

Abstracts and Citations

“…Furthermore, these circuits within the cingulate gyrus appear to have plasticity, suggesting an ability to adapt over recurrent stimuli. [2][3][4] In this study, the authors employed a relatively complex model to study the activation a pain aversion in a rat model. They used male Sprague-Dawley rats and induced pain with a hind paw injection of noxious stimulus or placebo injection.…”

“…Ketamine street use has already penetrated high school 12th graders. 4 I found no useful papers related to exposure and addiction/dependence. These authors, as do all of us using ketamine, owe the headache medicine community and our patients some long term follow up data regarding safety, tolerability, and any dependence conversion.…”

“…3 However, a recent randomized, double blind, placebo controlled trial comparing the response of a second IV dose of ketamine did not separate from placebo for treatmentresistant depression with suicidal ideation. 4 The question of prolonged benefit from intravenous ketamine in depression remains.…”

“…This protein has previously been used to study glial hyperactivity identified in chronic low back pain, and appears to be a reliable marker for centralized pain within the spinal cord. 4 This study evaluated the differences in brain TSPO binding between healthy controls and patients with fibromyalgia, and demonstrated an elevation in signal suggestive of microglia hyperexcitation. Interestingly, there was no greater amount of increase in the ligand associated with astrocytic hyperactivity, suggesting the predominant source of inflammatory response came from glial cells and not the surrounding astrocytes in this model.…”

“…3 Anesthetic delivery to the sphenopalatine ganglion may be an effective treatment for acute migraine, including treating nausea and emesis. 4 In this randomized, placebo-controlled study, patients undergoing an elective sinus procedure requiring general anesthetic received either an injection of 2 mL of 2% lidocaine with epinephrine or saline to the sphenopalatine foramen. Postoperative nausea and emesis were dramatically reduced by this simple procedure.…”